Ordinary Rebalance | Solactive China Biotech Index | Effective Date 15th January 2024
In the ordinary rebalance, the following composition will be implemented effective open 15.01.2024:
| AKESO INC |
| APELOA PHARMACEUTICAL CO-A |
| BEIJING TIANTAN BIOLOGICAL-A |
| BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO LTD |
| BETTA PHARMACEUTICALS CO L-A |
| BGI GENOMICS CO LTD-A |
| CHINA MEDICAL SYSTEM HOLDINGS LTD |
| CHINA NATIONAL MEDICINES-A |
| GAN & LEE PHARMACEUTICALS -A |
| GENSCRIPT BIOTECH CORP |
| HANSOH PHARMACEUTICAL GROUP CO |
| HUALAN BIOLOGICAL ENGINEER-A |
| HUBEI JUMPCAN PHARMACEUT-A |
| HUTCHMED CHINA LTD |
| HYGEIA HEALTHCARE HOLDINGS CO LTD |
| INNOVENT BIOLOGICS INC |
| JIANGSU HENGRUI MEDICINE CO LTD CLASS A |
| LIVZON PHARMACEUTICAL GROU-A |
| MGI ORD A |
| NANJING KING-FRIEND BIOCHEMICAL PHARMACEUTICAL CO LTD |
| REMEGEN CO LTD-A |
| SHANGHAI JUNSHI BIOSCIENCE |
| SHANGHAI RAAS BLOOD PRODUC-A |
| SHENYANG XINGQI PHARMACEUT-A |
| SHENZHEN KANGTAI BIOLOGICA-A |
| SINO BIOPHARMACEUTICAL LTD ORD |
| WALVAX BIOTECHNOLOGY CO-A |
| WUXI APPTEC CO LTD-A |
| WUXI BIOLOGICS CAYMAN INC |
| ZAI LAB LTD |